Navigation Links
New device can reduce sleep apnea episodes by 70 percent, Pitt-UPMC study shows
Date:1/8/2014

PITTSBURGH, Jan. 8, 2014 Implantation of a sleep apnea device called Inspire Upper Airway Stimulation (UAS) therapy can lead to significant improvements for patients with obstructive sleep apnea (OSA), according to a study published today in the New England Journal of Medicine. After one year, patients using the device had an approximately 70 percent reduction in sleep apnea severity, as well as significant reductions in daytime sleepiness.

The multicenter, prospective Stimulation Therapy for Apnea Reduction (STAR) trial was conducted at 22 medical centers in the United States and Europe, and is the first to evaluate the use of upper airway stimulation for sleep apnea.

OSA, which affects more than 8 million men and 4 million women in the U.S. and is twice as common in men, is characterized by repeated episodes of upper airway collapse during sleep, due to narrowing or blockage. Patients with OSA stop breathing, known as apnea, frequently during sleep, often for a minute or longer, and over half of those with OSA are overweight. Repeated episodes of apnea can lead to daytime fatigue, and increase a person's risk for heart attack, stroke, high blood pressure and even death.

Treatments for OSA include weight loss, upper airway surgeries, oral appliances, and continuous positive airway pressure (CPAP), which is considered the primary treatment for OSA.

"While CPAP is a successful treatment when used on a regular basis, as many as half of the patients who have been prescribed CPAP are unable to use it regularly, largely due to discomfort with the mask and/or the lack of desire to be tethered to a machine," said Patrick Strollo, M.D., professor of medicine and clinical and translational science at the University of Pittsburgh School of Medicine, medical director of the UPMC Sleep Medicine Center, and lead author of the study. "The results of this trial show a huge potential for a new and effective treatment that can help millions of patients."

"Inspire UAS therapy differs from other traditional sleep apnea devices and surgical procedures in that it targets the muscle tone of the throat rather than just the anatomy," noted Ryan Soose, M.D., director of the UPMC Division of Sleep Surgery and assistant professor at the University of Pittsburgh School of Medicine, Department of Otolaryngology. "Two thirds of patients using the Inspire UAS therapy device had successful control of their OSA although even more reported improvement in snoring, daytime sleepiness and quality of life measures. Eighty-six percent of patients were still using the device every night at the one year mark, which compares very favorably to CPAP."

From 724 candidates initially screened, the STAR trial implanted and prospectively evaluated 126 moderate-to-severe OSA patients who had difficulty using or adhering to CPAP therapy:

  • 83 percent of the participants were men, the mean age was 54.5 years, and the mean body-mass index was 28.4.
  • All patients underwent surgery to implant the device. The device stimulates the nerve of the tongue during sleep, thereby enlarging and stabilizing the airway and improving control of breathing.
  • Surgical implantation of the upper-airway stimulation system was performed by otolaryngologists at 22 academic and private centers, including Ryan Soose, M.D., of UPMC Ear, Nose and Throat specialists.
  • The device was implanted in three areas: a stimulation electrode was placed on the hypoglossal nerve, which provides innervation to the muscles of the tongue; a sensing lead was placed between rib muscles to detect breathing effort; and a neurostimulator was implanted in the upper right chest, just below the clavicle bone.
  • Patients used a "controller" to turn on the device at night, so it is only used when the patient sleeps. The Inspire UAS therapy device is designed to sense breathing patterns and deliver mild stimulation to a patient's airway muscles to keep the airway open during sleep.
  • Using various sleep-disorder measuring systems, patients were found to experience 68 to 70 percent fewer sleep-apnea episodes per hour.

"My short-term memory has improved significantly, and the surgery has made a huge difference in my quality of life," said Kathy Gaberson, one of the study participants who used the Inspire therapy. "My apnea episodes went from 23 times an hour to just two."


'/>"/>

Contact: Cristina Mestre
MestreCA@upmc.edu
412-586-9776
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Related medicine news :

1. InventHelp Introduces Device to Optimize Air Flow in a Full-Face Mask (CBS-189)
2. Electrical Safety Devices & Accessories Procurement Research Report Now Available from IBISWorld
3. InventHelp Inventor Develops Infant Urine Collection Device (OCM-592)
4. Global Hernia Repair Devices Market is Expected to Reach USD5.9 Billion in 2019: Transparency Market Research
5. Scripps Health Launches Pilot Study of Wireless Vital Signs Device
6. The Herbst Device by Respire Medical is FDA Cleared and Now Medicare PDAC Approved
7. DISQ: Dutch Speedskater Invents Mobile Fitness Training Device
8. CardioVet Introduces New Wireless Digital ECG Device to the Veterinary Market to Facilitate Cardiology Telemedicine Services
9. Global Enteral Feeding Devices Market 2012-2016
10. Ultrasound Devices Market (2D, 3D & 4D, Doppler, HIFU, ESWL) Worth $8.1 Billion by 2017 - New Report by MarketsandMarkets
11. Novel rehabilitation device improves motor skills after stroke
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New device can reduce sleep apnea episodes by 70 percent, Pitt-UPMC study shows
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the ... on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a business and ... April edition of American Veterinarian™. , “We look forward to launching ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... ... 27, 2017 , ... According to the American Cancer Society , the ... than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, ... to avoid this latter group, tune in to Lifestyle Magazine on April ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy ... resolve the pending litigation between itself and 1800 Vending DBA Healthy You Vending. ... “I am thrilled to announce that we have now reached a settlement agreement ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading ... bringing its latest products to the Deaf Seniors of America Conference, April 4-7 at ... to meet with knowledgeable ASL friendly staff from Harris Communications and to try out ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Medtec Europe will once ... 600 exhibitors from 70 countries the opportunity to ... will advance the medical technology industry. Taking place ... Stuttgart, Stuttgart, Germany , Medtec ... the key trends and insights across the entire ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
Breaking Medicine Technology: